Clinical trial · no report yet · Phase 3
CheckMate 722
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
- NCT02864251 ↗
- Completed
- Bristol-Myers Squibb
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 12 | |
| X threads | 11 | |
| YouTube | 9 |
The trial
ClinicalTrials.gov- Official title
- Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Nivolumab; Ipilimumab; Pemetrexed; Cisplatin; Carboplatin
- Arms
- Nivolumab+Platinum doublet chemotherapy · Experimental
- Nivolumab + Ipilimumab · Experimental
- Platinum doublet chemotherapy · Active comparator
- Enrollment
- 367
- Primary outcomes
- Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR)
- Sponsor
- Bristol-Myers Squibb with Ono Pharmaceutical Co., Ltd.
- Start
- Mar 17, 2017
- Primary completion
- Jan 20, 2022
- Results posted
- Yes
- Registry record
- NCT02864251 · updated Sep 28, 2023
Publications
linked from the registry- Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol. 2024 Apr 10;42(11):1252-1264. doi: 10.1200/JCO.23.01017. Epub 2024 Jan 22. PubMed 38252907